Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 184

Sort by

Sort Order Select

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Blood (2019) 134 (Supplement_1): 693.

https://doi.org/10.1182/blood-2019-125120

Published: 2019

Journal Articles

Prediction of Cardiac Complications in SCD

Alessia Pepe, MD, Laura Pistoia, Maria Rita Gamberini, MD, Silvia Macchi, MD, Francesca Valeria Commendatore, Elena Facchini, MD, Lorella Pitrolo, Mauro Celli, Aurelio Maggio, MD, Paolo Preziosi, Vincenzo Positano, Antonella Meloni, PhD

Blood (2019) 134 (Supplement_1): 1026.

https://doi.org/10.1182/blood-2019-121843

Published: 2019

Journal Articles

Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Maimoona Khan, MBBS, Asma Waheed, MBBS, Rida Ul Jannat, MBBS, Arafat Ali Ali Farooqui, MD, Muhammad Saad Farooqi, MD, Ali Younas Khan, MD, Madeeha Shafqat, Muhaddis Ejaz Ahmad, MD, Muhammad Abdullah Yousaf, MBBS, MD, Tariq Iqtidar Sadiq Syed, MD, Syed Maaz Abdullah, MBBS, Sravanthi Kotapati, MBBS, Irbaz Riaz, MDMMSc, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5588.

https://doi.org/10.1182/blood-2019-128833

Published: 2019

Journal Articles

Real-World Evidence of the Use of Carfilzomib and Dexamethasone (Kd) By Lenalidomide-Refractory Status: An Interim Analysis from a Prospective Observational Study

Xavier Leleu, MD PhD, Jo Caers, MD PhD, Barbara Gamberi, MD, Maaike Söhne, MD, Sonja Heibl, MD, Florence Suzan, MD, Abeera Mohammad, Sally Wetten, Evangelos Terpos, MD

Blood (2019) 134 (Supplement_1): 5578.

https://doi.org/10.1182/blood-2019-122938

Published: 2019

Journal Articles

Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

Blood (2019) 134 (Supplement_1): 3038.

https://doi.org/10.1182/blood-2019-126720

Published: 2019

Journal Articles

Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib

Moshe Yair Levy, MD, Lin Xie, MA, MS, Yuexi Wang, Frank Neumann, MD PhD, Shouryadeep Srivastava, MBBS, PhD, Daniel Naranjo, Jing Xu, Qisu Zhang, MPH, Mehul Dalal, PhD

Blood (2019) 134 (Supplement_1): 4751.

https://doi.org/10.1182/blood-2019-129053

Published: 2019

Journal Articles

Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia

Jeff P. Sharman, MD, John M Burke, MD, Habte A Yimer, MD, Michael A. Boxer, MD, Sunil Babu, MD, Jia Li, PhD, Yong Mun, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4317.

https://doi.org/10.1182/blood-2019-122482

Published: 2019

Journal Articles

Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)

Jennifer R. Brown, MD PhD, Matthew S. Davids, MD, Julie E Chang, MD, Shuo Ma, MD PhD, Juliana M L Biondo, MD, Yong Mun, PhD, Madlaina Breuleux, PhD, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 4320.

https://doi.org/10.1182/blood-2019-123665

Published: 2019

Journal Articles

Obinutuzumab-Related Adverse Events: A Systematic Review and Meta-Analysis

Irina Amitai, MD, Anat Gafter-Gvili, MD, Pia Raanani, MD, Ronit Gurion, MD

Blood (2019) 134 (Supplement_1): 5259.

https://doi.org/10.1182/blood-2019-128677

Published: 2019

Journal Articles

Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies

Ruben A. Mesa, MD, Moshe Talpaz, MD, Jean-Jacques Kiladjian, MD PhD, Claire N Harrison, Professor, Srdan Verstovsek, MD PhD, Sarah A Buckley, MD, Karisse Roman-Torres, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 4195.

https://doi.org/10.1182/blood-2019-124129

Published: 2019

Journal Articles

Treatment of Elderly Patients with Acute Promyelocytic Leukemia: A Real Life Experience of the "Rete Ematologica Lombarda"

Valentina Mancini, MD, Erika Borlenghi, MD, Livia Leuzzi, MD, Claudia Basilico, MD, Massimo Bernardi, MD, Patrizia Zappasodi, MD, Monica Fumagalli, MD, Elisabetta Todisco, MD PhD, Chiara Cattaneo, MD, Federico Lussana, MD, Giambattista Bertani, MD, Erika Ravelli, MD, Nicola Fracchiolla, Mauro Turrini, Giuseppe Rossi, Silvia Cantoni, Roberto Cairoli, MD

Blood (2019) 134 (Supplement_1): 3862.

https://doi.org/10.1182/blood-2019-130089

Published: 2019

Journal Articles

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

Giovanni Caocci, MD, Martino Deidda, Antonio Noto, Christian Cadeddu, Marianna Greco, Maria Pina Simula, Olga Mulas, Daniele Cocco, Claudia Fattuoni, Giuseppe Mercuro, Giorgio La Nasa

Blood (2019) 134 (Supplement_1): 4144.

https://doi.org/10.1182/blood-2019-124323

Published: 2019

Journal Articles

Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Laurie H Sehn, MD, Maurizio Martelli, MD, Marek Trněný, MD, Wenxin Liu, PhD, Christopher R Bolen, PhD, Andrea Knapp, PhD, Deniz Sahin, BSc, Gila Sellam, PhD, Umberto Vitolo

Blood (2019) 134 (Supplement_1): 4088.

https://doi.org/10.1182/blood-2019-123433

Published: 2019

Journal Articles

Cost Effective Cardio Protective Intervention in Haploidentical Hematopoietic Stem Cell Transplantation in Children - a Study from a Tertiary Care Centre in India

Revathi Raj, Ramya Uppuluri, MD, Venkateswaran Vellaichamy, MD, Nikila Ravichandran, MD, Kesavan Melarkode Ramanan, MD

Blood (2019) 134 (Supplement_1): 5866.

https://doi.org/10.1182/blood-2019-131539

Published: 2019

Journal Articles

The VITAL Trial: Phase II Trial of V osaroxin and I nfusional Cytarabine for Frontline T reatment of a cute Myeloid L eukemia

Stephen A Strickland, MD MSCI, Nikolai A. Podoltsev, MD PhD, Sanjay R Mohan, MD MSCI, Amer M. Zeidan, MBBS, MHS, Merrida A Childress, PhD, Gregory D Ayers, MS, Michael T Byrne, DO, Steven D. Gore, MD, Robert K. Stuart, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 180.

https://doi.org/10.1182/blood-2019-131520

Published: 2019

Journal Articles

Pomalidomide Reduces Bleeding and Alters Expression of Angiogenesis-Related Proteins in Patients with Hereditary Hemorrhagic Telangiectasia

Shadi Swaidani, MD PhD, Suman Kundu, MBA, Mohamed Samour, MBBS, Bernard Silver, MD, Joseph Parambil, MD, Sonia Thomas, DrPH, Keith R McCrae, MD

Blood (2019) 134 (Supplement_1): 5761.

https://doi.org/10.1182/blood-2019-127344

Published: 2019

Journal Articles

MCRN ¯ 003/MYX · 1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

Christopher P. Venner, MD FRCPC, Richard Leblanc, MDFRCPC, Irwindeep Sandhu, MDFRCPC, Darrell J. White, MD, Andrew R Belch, MD, Donna E Reece, MD, Christine I Chen, MD, Sean Dolan, MD, Andrea Kew, MDFRCP(C), Marc Lalancette, MD FRCP, Martha L Louzada, MD, Arleigh McCurdy, MD BSc, Gail T. McDonald, Tony Reiman, MD, Laura Rodriguez, Lois E. Shepherd, Engin Gul, BSc, Bingshu E. Chen, Annette E Hay

Blood (2018) 132 (Supplement 1): 1984.

https://doi.org/10.1182/blood-2018-99-117824

Published: 2018

Journal Articles

Genotypic Groups As Risk Factor for Cardiac MR Abnormalities and Complications in Thalassemia Major

Alessia Pepe, MD, Antonella Meloni, PhD, Stefano Salvadori, Silvia Macchi, MD, Angelantonio Vitucci, Mauro Murgia, MD, Aurelio Maggio, MD, Maria Flavia Fiorenza, Francesco Massei, Francesca Valeria Commendatore, Pietro Giuliano, Vincenzo Positano, Laura Pistoia

Blood (2018) 132 (Supplement 1): 1057.

https://doi.org/10.1182/blood-2018-99-112795

Published: 2018

Journal Articles

Clinical and Molecular Variables Associated with Atherosclerotic Vascular Disease in Myelodysplastic Syndromes

Mark G. Faber, DO, Amanda Przespolewski, DO, Jeffrey Baron, PharmD, Tara Cronin, BA, Wei Tan, MS, James E. Thompson, MD, Eunice S. Wang, MD, Elizabeth A. Griffiths, MD, Swapna Thota, MD

Blood (2018) 132 (Supplement 1): 4366.

https://doi.org/10.1182/blood-2018-99-110846

Published: 2018

Journal Articles

Antithrombotic Therapy Management in Patients with Inherited Bleeding Disorders and Ischaemic Heart Disease: A Single-Center Experience

Marie-Léa Piel-Julian, Marie-Françoise Thiercelin-Legrand, MD, Guillaume Moulis, MD PhD, Sophie Voisin, MD, Ségolène Claeyssens, Laurent Sailler, MD PhD

Blood (2018) 132 (Supplement 1): 1213.

https://doi.org/10.1182/blood-2018-99-117101

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Prediction of Cardiac Complications in SCD

Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Real-World Evidence of the Use of Carfilzomib and Dexamethasone (Kd) By Lenalidomide-Refractory Status: An Interim Analysis from a Prospective Observational Study

Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib

Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia

Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)

Obinutuzumab-Related Adverse Events: A Systematic Review and Meta-Analysis

Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies

Treatment of Elderly Patients with Acute Promyelocytic Leukemia: A Real Life Experience of the "Rete Ematologica Lombarda"

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Cost Effective Cardio Protective Intervention in Haploidentical Hematopoietic Stem Cell Transplantation in Children - a Study from a Tertiary Care Centre in India

The VITAL Trial: Phase II Trial of V osaroxin and I nfusional Cytarabine for Frontline T reatment of a cute Myeloid L eukemia

Pomalidomide Reduces Bleeding and Alters Expression of Angiogenesis-Related Proteins in Patients with Hereditary Hemorrhagic Telangiectasia

MCRN ¯ 003/MYX · 1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

Genotypic Groups As Risk Factor for Cardiac MR Abnormalities and Complications in Thalassemia Major

Clinical and Molecular Variables Associated with Atherosclerotic Vascular Disease in Myelodysplastic Syndromes

Antithrombotic Therapy Management in Patients with Inherited Bleeding Disorders and Ischaemic Heart Disease: A Single-Center Experience

Email alerts

ASH Publications

American Society of Hematology